The Adult AIDS Clinical Trials Group (ACTG) is a multicenter, multidisciplinary investigative group dedicated to the study of HIV-1 pathogenesis and therapy. Operating since 1987 under a collection of grants and contracts sponsored by the National Institute of Allergy and Infectious Diseases, the ACTG formerly addressed both adult and pediatric manifestations of HIV disease. Following a reorganization, there are now separate structures for an Adult ACTG and a Pediatric ACTG. This cooperative agreement concerns the Adult ACTG Central Group, which includes support for the Group Leader, the Executive Committee, other standing committees, a Community Constituency Group, the Operations Office, and the Advanced Technology Laboratories. Associated with the Central Group, under separate applications, are 22-29 AIDS Clinical Trial Units and a Statistical and Data Management Center. The Central Group will initiate 24-30 clinical trials per year that will enroll 2,500 to 3,500 study participants. The Group will be managed by an Executive Committee that will oversee an integrated research agenda developed by three Research Advisory Committees (HIV Disease, Complications of HIV Disease, and Immunology/Immune-Based Therapy). The structure of the Adult ACTG has been designed to provide a mechanism for a coordinated response to rapidly changing investigative opportunities. Clinical trials will be designed to delineate therapeutic approaches that both improve the survival and quality of life for persons with HIV-1 infection and make use of therapeutic interventions to further define the pathogenesis of HIV-1 infection. The increased emphasis on the investigation of HIV-1 pathogenesis is reflected by a major increase in the resources devoted to laboratory investigation. The ACTG will devote considerable effort and resources to the recruitment and retention of individuals that reflect the changing demographics of the AIDS epidemic. This effort is reflected in recruitment plans of individual units, and by the inclusion of four clinical trials units based at traditionally minority institutions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI038858-04
Application #
2856036
Study Section
Special Emphasis Panel (SRC (81))
Program Officer
Batzold, Frederick
Project Start
1996-01-01
Project End
1999-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Social and Scientific Systems, Inc.
Department
Type
DUNS #
City
Silver Spring
State
MD
Country
United States
Zip Code
20910
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Stein, James H; Yeh, Eunice; Weber, Joanne M et al. (2018) Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate. Arterioscler Thromb Vasc Biol 38:2870-2878
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Kelesidis, Theodoros; Moser, Carlee B; Johnston, Elizabeth et al. (2018) Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. J Acquir Immune Defic Syndr 78:362-366
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Jennings, Cheryl; Wager, Carrie G; Scianna, Salvatore R et al. (2018) Use of External Quality Control Material for HIV-1 RNA Testing To Assess the Comparability of Data Generated in Separate Laboratories and the Stability of HIV-1 RNA in Samples after Prolonged Storage. J Clin Microbiol 56:

Showing the most recent 10 out of 648 publications